top of page
Valfard Therapeutics is advancing a targeted, enzyme-responsive injectable therapy for chronic diabetic foot ulcers (DFUs) — a $14.4B global unmet need. Their lead candidate delivers transforming growth factor-beta (TGF-β) in response to elevated MMP-9 levels in chronic wounds, promoting optimal healing conditions and reducing amputation risk. With a biomaterials-driven approach and strong scientific leadership, Valfard aims to transform wound care with a true disease-modifying therapy.

Lead Program & Pipeline

  • Lead candidate: Subcutaneous injectable therapy delivering TGF-β for DFU treatment

  • Uses enzyme-responsive biomaterial to trigger drug release in MMP-9-rich chronic wounds

  • Targets inflammation resolution and tissue regeneration, addressing root causes of chronic DFUs

  • Preclinical stage with in-vitro optimization and primate model studies underway

  • IP strategy in development; provisional patent filings planned

Technology Differentiators

  • First DFU therapy to leverage MMP-9–triggered drug release for responsive, localized healing

  • Provides sustained release of bioactive TGF-β, enhancing wound resolution

  • Designed to overcome limitations of current DFU treatments, which only manage symptoms

  • Platform may be applicable to other chronic wound types in dermatology and endocrinology

Stage & Investment

  • Stage: Preclinical (in-vitro optimization and primate model development)

  • Funding Raised: <$500K

  • IP: Not yet filed; provisional applications in progress

  • Collaborations: In discussion with CRO partners for non-clinical development

What's Next

  • Finalize optimization of in-vitro release kinetics

  • Initiate and complete primate model studies

  • File provisional patents for biomaterial platform

  • Form an independent Board of Directors with clinical and business leaders

  • Raise seed funding and pursue strategic partnerships with hospitals, payers, and pharma

Leadership

Zikria-Saif.jpg
Zikria Saif
CEO & Co-founder
1521837550873.jpg
Neha Chauhan, PhD
Co-founder
bottom of page